Investigational drug · Phase 3
AXS-14
Also called: Esreboxetine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fibromyalgia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "AXS-14"
First trial start
2026
Jan 14, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AXS-14", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fibromyalgia
Largest trials
Live from ClinicalTrials.gov: studies naming "AXS-14" as an intervention, largest first.
- Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research DesignPivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07398417 · 620 participants (planned) · Start Jan 14, 2026 · Primary completion Mar 2028
Drug: AXS-14 (Esreboxetine); Placebo · For: Fibromyalgia
Sites: Glendale, Arizona; Phoenix, Arizona; Tucson, Arizona · 57 sites in all
- Open-Label Safety Study of AXS-14 in Subjects With FibromyalgiaPivotal-lookingEnrolling by invitation
Axsome Therapeutics, Inc.Industry
NCT07637162 · 300 participants (planned) · Start Apr 29, 2026 · Primary completion May 2028
Drug: AXS-14 (esreboxetine) · For: Fibromyalgia
Sites: Little Rock, Arkansas; Anaheim, California; Oceanside, California · 38 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) for Treatment of Fibromyalgia: A Comprehensive Clinical Review.
Malik A, Brown Z, Ryder A, et al. · Psychopharmacol Bull 2025
- Recent strategies for drug development in fibromyalgia syndrome.
Blumenthal DE, Malemud CJ · Expert Rev Neurother 2016
- Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.
Fujimori I, Yukawa T, Kamei T, et al. · Bioorg Med Chem 2015
- Relative contributions of norepinephrine and serotonin transporters to antinociceptive synergy between monoamine reuptake inhibitors and morphine in the rat formalin model.
Shen F, Tsuruda PR, Smith JA, et al. · PLoS One 2013
- Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial.
Arnold LM, Hirsch I, Sanders P, et al. · Arthritis Rheum 2012
- Safety and efficacy of esreboxetine in patients with fibromyalgia: An 8-week, multicenter, randomized, double-blind, placebo-controlled study.
Arnold LM, Chatamra K, Hirsch I, et al. · Clin Ther 2010
Also in development for Fibromyalgia
- ONO-1110Phase 25 trials
Ono Pharmaceutical Co., Ltd. · Fibromyalgia, Social Anxiety Disorder (SAD), Major Depressive Disorder (MDD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.